Linagliptina Intas

Linagliptin, the active ingredient in Linagliptina Intas, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise. GNH USA supplies Linagliptina Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glucose regulation.

Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c levels. Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control when metformin alone is insufficient. Type 2 diabetes mellitus (add‑on to insulin): may reduce required insulin dose while maintaining target glucose levels.

Linagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort. - Upper respiratory infection: cough, sore throat. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: angioedema, anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bullous pemphigoid: autoimmune blistering skin disease. - Hypoglycaemia: when combined with insulin or sulfonylureas.

Linagliptin should be used with consideration of patient‑specific factors and monitoring requirements.

Renal impairment: no dose adjustment required, but monitor renal function regularly. Hepatic impairment: use with caution; monitor liver enzymes. Cardiovascular disease: assess risk and monitor for any cardiac events. Pregnancy and breastfeeding: safety not established; avoid unless benefit outweighs risk. Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce plasma concentrations of linagliptin. - Combination with insulin or sulfonylureas: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., itraconazole): may increase linagliptin exposure. - Diuretics: may affect renal clearance, requiring monitoring. - Warfarin: potential alteration of INR; monitor coagulation parameters.